Lactoferrin deficiency promotes colitis-associated colorectal dysplasia in mice

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Ye, Qiurong ^a   Zheng, Ying ^b   Fan, Songqing ^c   Qin, Zailong ^a   Li, Nan ^d   Tang, Anliu ^d   Ai, Feiyan ^d   Zhang, Xuemei ^d   Bian, Yanhui ^a   Dang, Wei ^a   Huang, Jing ^a   Zhou, Ming ^a   Zhou, Yanhong ^a   Xiong, Wei ^a   Yan, Qun ^e   Ma, Jian ^a   Li, Guiyuan ^a  

^a HUNAN CANCER HOSPITAL   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^e CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; DEXTRAN SULFATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTOFERRIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; LTF PROTEIN, HUMAN; LTF PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; COLITIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; LF GENE; MALE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; CHEMICALLY INDUCED; COLONIC NEOPLASMS; DISEASE MODEL; DOWN REGULATION; GENE INACTIVATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY;

ANIMALS; APOPTOSIS; AZOXYMETHANE; CELL PROLIFERATION; COLITIS; COLONIC NEOPLASMS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE KNOCKOUT TECHNIQUES; HUMANS; INFLAMMATION; LACTOFERRIN; MALE; MICE; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84904891476     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103298     Document Type: Article

References (39)

1. Legrand D (2012) Lactoferrin, a key molecule in immune and inflammatory processes. Biochem Cell Biol 90: 252-268.
2. Legrand D, Pierce A, Elass E, Carpentier M, Mariller C, et al. (2008) Lactoferrin structure and functions. Adv Exp Med Biol 606: 163-194.
3. Deng M, Ye Q, Qin Z, Zheng Y, He W, et al. (2013) miR-214 promotes tumorigenesis by targeting lactotransferrin in nasopharyngeal carcinoma. Tumour Biol 34: 1793-1800.
4. Bezault J, Bhimani R, Wiprovnick J, Furmanski P (1994) Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res 54: 2310-2312. (Pubitemid 24138715)
5. Li WY, Li QW, Han ZS, Jiang ZL, Yang H, et al. (2011) Growth suppression effects of recombinant adenovirus expressing human lactoferrin on cervical cancer in vitro and in vivo. Cancer Biother Radiopharm 26: 477-483.
6. Matsuda Y, Saoo K, Hosokawa K, Yamakawa K, Yokohira M, et al. (2007) Post-initiation chemopreventive effects of dietary bovine lactoferrin on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in female A/J mice. Cancer Lett 246: 41-46. (Pubitemid 44959376)
7. Sekine K, Watanabe E, Nakamura J, Takasuka N, Kim DJ, et al. (1997) Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats. Jpn J Cancer Res 88: 523-526. (Pubitemid 27348486)
8. Tsuda H, Sekine K, Nakamura J, Ushida Y, Kuhara T, et al. (1998) Inhibition of azoxymethane initiated colon tumor and aberrant crypt foci development by bovine lactoferrin administration in F344 rats. Adv Exp Med Biol 443: 273-284. (Pubitemid 28432197)
9. Varadhachary A, Wolf JS, Petrak K, O'Malley BW Jr, Spadaro M, et al. (2004) Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int J Cancer 111: 398-403. (Pubitemid 38998820)
10. Xiong W, Zeng ZY, Xia JH, Xia K, Shen SR, et al. (2004) A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res 64: 1972-1974. (Pubitemid 38339442)
11. Zhou Y, Zeng Z, Zhang W, Xiong W, Wu M, et al. (2008) Lactotransferrin: a candidate tumor suppressor-Deficient expression in human nasopharyngeal carcinoma and inhibition of NPC cell proliferation by modulating the mitogen-activated protein kinase pathway. Int J Cancer 123: 2065-2072.
12. Deng M, Zhang W, Tang H, Ye Q, Liao Q, et al. (2013) Lactotransferrin acts as a tumor suppressor in nasopharyngeal carcinoma by repressing AKT through multiple mechanisms. Oncogene 32: 4273-4283.
13. Casado B, Pannell LK, Iadarola P, Baraniuk JN (2005) Identification of human nasal mucous proteins using proteomics. Proteomics 5: 2949-2959. (Pubitemid 41059771)
14. Legrand D, Mazurier J (2010) A critical review of the roles of host lactoferrin in immunity. Biometals 23: 365-376.
15. Ward PP, Mendoza-Meneses M, Cunningham GA, Conneely OM (2003) Iron status in mice carrying a targeted disruption of lactoferrin. Mol Cell Biol 23: 178-185. (Pubitemid 36008511)
16. Ward PP, Mendoza-Meneses M, Park PW, Conneely OM (2008) Stimulus-dependent impairment of the neutrophil oxidative burst response in lactoferrin-deficient mice. Am J Pathol 172: 1019-1029. (Pubitemid 351519998)
17. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
18. Tang A, Li N, Li X, Yang H, Wang W, et al. (2012) Dynamic activation of the key pathways: linking colitis to colorectal cancer in a mouse model. Carcinogenesis 33: 1375-1383.
19. Barrett CW, Fingleton B, Williams A, Ning W, Fischer MA, et al. (2011) MTGR1 is required for tumorigenesis in the murine AOM/DSS colitisassociated carcinoma model. Cancer Res 71: 1302-1312.
20. Rao C, Shetty J, Prasad KH (2013) Immunohistochemical profile and morphology in triple - negative breast cancers. J Clin Diagn Res 7: 1361-1365.
21. Khamas A, Ishikawa T, Shimokawa K, Mogushi K, Iida S, et al. (2012) Screening for epigenetically masked genes in colorectal cancer Using 5-Aza-2′-deoxycytidine, microarray and gene expression profile. Cancer Genomics Proteomics 9: 67-75.
22. Inubushi T, Kawazoe A, Miyauchi M, Kudo Y, Ao M, et al. (2012) Molecular mechanisms of the inhibitory effects of bovine lactoferrin on lipopolysaccharide-mediated osteoclastogenesis. J Biol Chem 287: 23527-23536.
23. Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18: 2195-2224.
24. Kanwar RK, Kanwar JR (2013) Immunomodulatory lactoferrin in the regulation of apoptosis modulatory proteins in cancer. Protein Pept Lett 20: 450-458.
25. Wang J, Li Q, Ou Y, Han Z, Li K, et al. (2011) Inhibition of tumor growth by recombinant adenovirus containing human lactoferrin through inducing tumor cell apoptosis in mice bearing EMT6 breast cancer. Arch Pharm Res 34: 987-995.
26. Xu XX, Jiang HR, Li HB, Zhang TN, Zhou Q, et al. (2010) Apoptosis of stomach cancer cell SGC-7901 and regulation of Akt signaling way induced by bovine lactoferrin. J Dairy Sci 93: 2344-2350.
27. Hassman LM, Ellison TJ, Kedes DH (2011) KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation. J Clin Invest 121: 752-768.
28. Kumar A, Rajendran V, Sethumadhavan R, Purohit R (2013) AKT kinase pathway: a leading target in cancer research. ScientificWorldJournal 2013: 756134.
29. Velusamy SK, Ganeshnarayan K, Markowitz K, Schreiner H, Furgang D, et al. (2013) Lactoferrin knockout mice demonstrates greater susceptibility to Aggregatibacter actinomycetemcomitans-induced periodontal disease. J Periodontol 84: 1690-1701.
30. Velusamy SK, Poojary R, Ardeshna R, Alabdulmohsen W, Fine DH, et al. (2014) Protective effects of human lactoferrin during Aggregatibacter actinomy-cetemcomitans-induced bacteremia in lactoferrin-deficient mice. Antimicrob Agents Chemother 58: 397-404.
31. Boivin GP, Washington K, Yang K, Ward JM, Pretlow TP, et al. (2003) Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 124: 762-777. (Pubitemid 36268493)
32. Kuhara T, Yamauchi K, Tamura Y, Okamura H (2006) Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL-18 and type I IFN in the small intestine. J Interferon Cytokine Res 26: 489-499. (Pubitemid 44061089)
33. Lanas A, Ortego J, Sopena F, Alcedo J, Barrio E, et al. (2007) Effects of long-term cyclo-oxygenase 2 selective and acid inhibition on Barrett's oesophagus. Aliment Pharmacol Ther 26: 913-923. (Pubitemid 47346706)
34. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, et al. (2008) Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118: 560-570. (Pubitemid 351206546)
35. Ma J, Guan R, Shen H, Lu F, Xiao C, et al. (2013) Comparison of anticancer activity between lactoferrin nanoliposome and lactoferrin in Caco-2 cells in vitro. Food Chem Toxicol 59: 72-77.
36. Fujita K, Matsuda E, Sekine K, Iigo M, Tsuda H (2004) Lactoferrin enhances Fas expression and apoptosis in the colon mucosa of azoxymethane-treated rats. Carcinogenesis 25: 1961-1966. (Pubitemid 39405916)
37. Park S, Regmi SC, Park SY, Lee EK, Chang JH, et al. (2014) Protective effect of 7-O-succinyl macrolactin A against intestinal inflammation is mediated through PI3-kinase/Akt/mTOR and NF-kappaB signaling pathways. Eur J Pharmacol 735: 184-192.
38. Heron-Milhavet L, Franckhauser C, Rana V, Berthenet C, Fisher D, et al. (2006) Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding. Mol Cell Biol 26: 8267-8280. (Pubitemid 44748563)
39. Robb VA, Astrinidis A, Henske EP (2006) Frequent of hyperphosphorylation of ribosomal protein S6 hyperphosphorylation in lymphangioleiomyomatosis- associated angiomyolipomas. Mod Pathol 19: 839-846. (Pubitemid 43780454)